<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03332771</url>
  </required_header>
  <id_info>
    <org_study_id>EFC14838</org_study_id>
    <secondary_id>2016-001801-17</secondary_id>
    <secondary_id>U1111-1190-7596</secondary_id>
    <nct_id>NCT03332771</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy</brief_title>
  <acronym>SOTA-GLIM</acronym>
  <official_title>A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Placebo Added to Metformin in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lexicon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lexicon Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To demonstrate the non-inferiority of Sotagliflozin 400 milligrams (mg) compared to&#xD;
      Glimepiride on hemoglobin A1c (HbA1c) reduction at Week 52 in participants with Type 2&#xD;
      Diabetes (T2D) who have inadequate glycemic control with metformin.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      To demonstrate the superiority of Sotagliflozin 400 mg compared to Glimepiride on change in&#xD;
      body weight, systolic blood pressure (SBP) in participants with baseline SBP ≥130 millimeter&#xD;
      of mercury (mmHg), SBP in all participants, and proportion of participants with at least 1&#xD;
      documented symptomatic hypoglycemic event (≤70 milligrams per deciliter [mg/dL]).&#xD;
&#xD;
        -  To demonstrate the superiority of Sotagliflozin 400 mg compared to placebo on change in&#xD;
           HbA1c, body weight, SBP in participants with baseline SBP ≥130 mmHg, SBP in all&#xD;
           participants.&#xD;
&#xD;
        -  To demonstrate the superiority of Sotagliflozin 200 mg compared to placebo on change in&#xD;
           HbA1c.&#xD;
&#xD;
        -  To demonstrate the non-inferiority of Sotagliflozin 400 mg compared to Glimepiride on&#xD;
           change in HbA1c.&#xD;
&#xD;
        -  To demonstrate the superiority of Sotagliflozin 400 mg compared to Glimepiride on change&#xD;
           in HbA1c.&#xD;
&#xD;
        -  To evaluate the safety and tolerability of Sotagliflozin compared to Glimepiride and&#xD;
           placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 58 weeks, including a Screening Period consisting of a Screening phase of up to 2&#xD;
      weeks, a 2-week single-blind placebo Run-in phase, a 52-week double-blind Treatment Period,&#xD;
      and a 2-week post-treatment Follow-up period to collect safety information.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Actual">September 6, 2019</completion_date>
  <primary_completion_date type="Actual">August 6, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Hemoglobin A1c at Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>An analysis of covariance (ANCOVA) model was used for the analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hemoglobin A1c at Week 26</measure>
    <time_frame>Baseline, Week 26</time_frame>
    <description>An ANCOVA model was used for the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Week 26 and 52</measure>
    <time_frame>Baseline, Week 26, Week 52</time_frame>
    <description>An ANCOVA model was used for the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure (SBP) for Participants With SBP ≥130 mmHg at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>An ANCOVA model was used for the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure (SBP) for All Participants at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>An ANCOVA model was used for the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With At Least One Documented Symptomatic Hypoglycemic Event</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Documented symptomatic hypoglycemia includes the typical symptoms of hypoglycemia (increased sweating, nervousness, asthenia/weakness, tremor, dizziness, increased appetite, palpitations, headache, sleep disorder, confusion, seizures, unconsciousness, and/or coma) and plasma glucose ≤ 70 mg/dL (3.9 mmol/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs)</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Participants With Hypoglycemic Events</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>Percentage of participants with hypoglycemic events are reported for the following 3 categories: Any hypoglycemia (as reported in the Electronic Case Report Form); Documented symptomatic hypoglycemia [typical symptoms of hypoglycemia (increased sweating, nervousness, asthenia/weakness, tremor, dizziness, increased appetite, palpitations, headache, sleep disorder, confusion, seizures, unconsciousness, and/or coma) and plasma glucose ≤ 70 mg/dL (3.9 mmol/L)]; Severe [an event requiring assistance of another person to actively administer carbohydrate, glucagon, intravenous glucose or other resuscitative actions] or documented symptomatic hypoglycemia [typical symptoms of hypoglycemia and plasma glucose ≤ 70 mg/dL].</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">954</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Sotagliflozin 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following a 2-week run-in period, two Sotagliflozin 200 mg, tablets, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sotagliflozin 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following a 2-week run-in period, one Sotagliflozin 200 mg, tablet and one Sotagliflozin-matching placebo tablet, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glimepiride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets, and combination of two Glimepiride capsules with adequate dose strengths per dose titration (titrated up to 6mg), taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sotagliflozin (SAR439954)</intervention_name>
    <description>Pharmaceutical form: tablet&#xD;
Route of administration: oral</description>
    <arm_group_label>Sotagliflozin 200 mg</arm_group_label>
    <arm_group_label>Sotagliflozin 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>Pharmaceutical form: capsule&#xD;
Route of administration: oral</description>
    <arm_group_label>Glimepiride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Pharmaceutical form: tablet&#xD;
Route of administration: oral</description>
    <arm_group_label>Glimepiride</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Sotagliflozin 200 mg</arm_group_label>
    <arm_group_label>Sotagliflozin 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: tablet&#xD;
Route of administration: oral</description>
    <arm_group_label>Glimepiride</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Sotagliflozin 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: capsule&#xD;
Route of administration: oral</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Sotagliflozin 200 mg</arm_group_label>
    <arm_group_label>Sotagliflozin 400 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Participants with Type 2 Diabetes (T2D) treated with metformin at a stable dose ≥1500&#xD;
             milligrams per day (mg/day) or maximum tolerated dose (documented) for at least 12&#xD;
             weeks prior to Screening Visit; in case of documented lack of tolerance, metformin&#xD;
             dose &lt;1500 mg/day is acceptable, and the dose should be stable for at least 12 weeks&#xD;
             prior to Screening Visit.&#xD;
&#xD;
          -  Participants has given written informed consent to participate in the study in&#xD;
             accordance with local regulations.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Age &lt;18 years at the Screening Visit or &lt;legal age of majority, whichever is greater.&#xD;
&#xD;
          -  Type 1 diabetes mellitus.&#xD;
&#xD;
          -  HbA1c, HbA1c &lt;7.0% or HbA1c &gt;10% at Screening.&#xD;
&#xD;
          -  Fasting Plasma Glucose (FPG) &gt;15 millimoles per liter (mmol/L) (&gt;270 milligram per&#xD;
             deciliter [mg/dL]) measured by the central laboratory at Screening (Visit 1) and&#xD;
             confirmed by a repeat test (&gt;15 mmol/L [&gt;270 mg/dL]) before randomization.&#xD;
&#xD;
          -  Body mass index ≤20 or &gt;45 kilogram per meter square (kg/m^2) at Screening.&#xD;
&#xD;
          -  Pregnant (confirmed by pregnancy test at the Screening) or breast-feeding women.&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) not willing to use highly effective method(s)&#xD;
             of birth control during the study treatment period and the follow-up period, or who&#xD;
             are unwilling or unable to be tested for pregnancy (see Appendix A) during the study.&#xD;
&#xD;
          -  Previous use of any antidiabetic drug other than Metformin within 12 weeks preceding&#xD;
             the Screening Visit.&#xD;
&#xD;
          -  Use of a selective Sodium-glucose co-transporter-2 (SGLT2) inhibitor (e.g.,&#xD;
             Canagliflozin, Dapagliflozin, or Empagliflozin) within 3 months prior to the Screening&#xD;
             visit.&#xD;
&#xD;
          -  Use of systemic glucocorticoids (excluding topical, or ophthalmic application,&#xD;
             intra-articular, nasal spray or inhaled forms) for more than 10 consecutive days&#xD;
             within 90 days prior to the Screening Visit.&#xD;
&#xD;
          -  Previous insulin use &gt;1 month (at any time, except for treatment of gestational&#xD;
             diabetes).&#xD;
&#xD;
          -  History of prior gastric surgical procedure, including gastric banding, or&#xD;
             inflammatory bowel disease within 3 years prior to the Screening Visit.&#xD;
&#xD;
          -  Difficulty swallowing such that the participants cannot take the investigational&#xD;
             medicinal product (IMP).&#xD;
&#xD;
          -  History of diabetic ketoacidosis or nonketotic hyperosmolar coma within 12 weeks prior&#xD;
             to the Screening Visit.&#xD;
&#xD;
          -  Mean of 3 separate blood pressure measurements &gt;180 millimeter of mercury (mmHg) (SBP)&#xD;
             or &gt;100 mmHg (DBP).&#xD;
&#xD;
          -  History of hypertensive emergency within 12 weeks prior to Screening.&#xD;
&#xD;
          -  Participants who have previously been randomized in any clinical trial of&#xD;
             Sotagliflozin/LX4211.&#xD;
&#xD;
          -  Participants with severe renal disease as defined by an estimated glomerular&#xD;
             filtration rate (eGFR) of &lt;30 milliliter per minute per meter square (mL/min/1.73 m^2)&#xD;
             at Screening, based on the 4 variable Modification of Diet in Renal Disease (MDRD)&#xD;
             equation (or according to the renal function restrictions of metformin use defined in&#xD;
             the local approved label).&#xD;
&#xD;
          -  Participants with severe anemia, severe cardiovascular (including congestive heart&#xD;
             failure New York Heart Association IV), respiratory, hepatic, neurological,&#xD;
             psychiatric, or active malignant tumor or other major systemic disease that, according&#xD;
             to Investigator, will preclude their safe participation in this study, or will make&#xD;
             implementation of the protocol or interpretation of the study results difficult.&#xD;
&#xD;
          -  Aspartate aminotransferase and/or alanine aminotransferase: &gt;3 times the upper limit&#xD;
             of the normal laboratory range (ULN).&#xD;
&#xD;
          -  Total bilirubin: &gt;1.5 times ULN (except in case of Gilbert's syndrome).&#xD;
&#xD;
          -  Participants who have taken other investigational drugs within 12 weeks or 5&#xD;
             half-lives from Screening whichever is longer.&#xD;
&#xD;
          -  Participants unwilling or unable to perform self-monitoring blood glucose (SMBG),&#xD;
             complete the participant diary, or comply with study visits and other study procedures&#xD;
             as required per protocol.&#xD;
&#xD;
          -  Participants with contraindication to glimepiride as per local labelling.&#xD;
&#xD;
          -  Participants with contraindication to metformin as per local labelling.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a&#xD;
        Participants potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suman Wason, MD</last_name>
    <role>Study Director</role>
    <affiliation>Lexicon Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 8407040</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407048</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233-2110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407035</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407051</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801-2417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407065</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407078</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407089</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407011</name>
      <address>
        <city>Gold River</city>
        <state>California</state>
        <zip>95670</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407044</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407006</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255-2911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407037</name>
      <address>
        <city>Lemon Grove</city>
        <state>California</state>
        <zip>91945</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407100</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <zip>90717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407033</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407019</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057-3507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407098</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325-5409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407094</name>
      <address>
        <city>Norwalk</city>
        <state>California</state>
        <zip>90650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407106</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91766</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407096</name>
      <address>
        <city>Rancho Cucamonga</city>
        <state>California</state>
        <zip>91730</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407036</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407084</name>
      <address>
        <city>Tarzana</city>
        <state>California</state>
        <zip>91356-3551</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407034</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786-4070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407032</name>
      <address>
        <city>Van Nuys</city>
        <state>California</state>
        <zip>91405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407004</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407117</name>
      <address>
        <city>Wildomar</city>
        <state>California</state>
        <zip>92595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407045</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80920-8075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407074</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407027</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407103</name>
      <address>
        <city>Cooper City</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407021</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407062</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407121</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407024</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32825-4454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407038</name>
      <address>
        <city>Palmetto Bay</city>
        <state>Florida</state>
        <zip>33157-5503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407093</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026-3924</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407107</name>
      <address>
        <city>Spring Hill</city>
        <state>Florida</state>
        <zip>34609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407091</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33619</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407113</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33634</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407092</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407115</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407017</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407018</name>
      <address>
        <city>Elgin</city>
        <state>Illinois</state>
        <zip>60124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407046</name>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <zip>60031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407119</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407075</name>
      <address>
        <city>Waterloo</city>
        <state>Iowa</state>
        <zip>50702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407120</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407095</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606-2806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407083</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205-1138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407043</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503-2517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407087</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407060</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407058</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407009</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407079</name>
      <address>
        <city>Zachary</city>
        <state>Louisiana</state>
        <zip>70791-4010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407085</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407001</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407069</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098-6334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407110</name>
      <address>
        <city>Olive Branch</city>
        <state>Mississippi</state>
        <zip>38654</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407054</name>
      <address>
        <city>Bridgeton</city>
        <state>Missouri</state>
        <zip>63044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407049</name>
      <address>
        <city>Norfolk</city>
        <state>Nebraska</state>
        <zip>68701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407039</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407061</name>
      <address>
        <city>Papillion</city>
        <state>Nebraska</state>
        <zip>68046-3136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407108</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106-4132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407050</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407116</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016-6402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407086</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407122</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407123</name>
      <address>
        <city>West Seneca</city>
        <state>New York</state>
        <zip>14224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407020</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407114</name>
      <address>
        <city>Lenoir</city>
        <state>North Carolina</state>
        <zip>28645-8981</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407015</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407030</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144-2742</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407041</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401-6638</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407101</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407099</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407081</name>
      <address>
        <city>Lyndhurst</city>
        <state>Ohio</state>
        <zip>44124-2467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407057</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407073</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104-3252</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407068</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407104</name>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <zip>15009-1957</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407025</name>
      <address>
        <city>Hatboro</city>
        <state>Pennsylvania</state>
        <zip>19040-2045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407053</name>
      <address>
        <city>Lansdale</city>
        <state>Pennsylvania</state>
        <zip>19446-1002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407016</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407071</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651-1817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407022</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407031</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407014</name>
      <address>
        <city>Jefferson City</city>
        <state>Tennessee</state>
        <zip>37760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407002</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37938</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407056</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407026</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78735-8982</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407029</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407070</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407102</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78414-4173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407023</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407111</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407013</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76164</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407080</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407088</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77095-2856</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407090</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407042</name>
      <address>
        <city>Lampasas</city>
        <state>Texas</state>
        <zip>76550-1820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407067</name>
      <address>
        <city>Lufkin</city>
        <state>Texas</state>
        <zip>75904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407118</name>
      <address>
        <city>Lufkin</city>
        <state>Texas</state>
        <zip>75904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407059</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407012</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75149</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407007</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407005</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407064</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3818</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407010</name>
      <address>
        <city>Schertz</city>
        <state>Texas</state>
        <zip>78154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407076</name>
      <address>
        <city>Splendora</city>
        <state>Texas</state>
        <zip>77372</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407063</name>
      <address>
        <city>Clinton</city>
        <state>Utah</state>
        <zip>84015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407055</name>
      <address>
        <city>Holladay</city>
        <state>Utah</state>
        <zip>84117-7054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407097</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407072</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84102-1553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407124</name>
      <address>
        <city>Manassas</city>
        <state>Virginia</state>
        <zip>20110-4421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407105</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8407028</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1007002</name>
      <address>
        <city>Gabrovo</city>
        <zip>5300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1007008</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1007003</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1007001</name>
      <address>
        <city>Ruse</city>
        <zip>7003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1007004</name>
      <address>
        <city>Smolyan</city>
        <zip>4700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1007009</name>
      <address>
        <city>Sofia</city>
        <zip>1632</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1007005</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1007006</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1007007</name>
      <address>
        <city>Varna</city>
        <zip>9000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3487005</name>
      <address>
        <city>Balatonfured</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3487001</name>
      <address>
        <city>Budapest</city>
        <zip>1033</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3487010</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3487006</name>
      <address>
        <city>Debrecen</city>
        <zip>4025</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3487008</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3487002</name>
      <address>
        <city>Kecskemet</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3487007</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4405</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3487004</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7037004</name>
      <address>
        <city>Bardejov</city>
        <zip>085 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7037008</name>
      <address>
        <city>Bratislava</city>
        <zip>831 06</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7037007</name>
      <address>
        <city>Bratislava</city>
        <zip>85101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7037005</name>
      <address>
        <city>Kosice</city>
        <zip>4014</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7037002</name>
      <address>
        <city>Levice</city>
        <zip>934 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7037010</name>
      <address>
        <city>Nitra</city>
        <zip>94901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7037009</name>
      <address>
        <city>Roznava</city>
        <zip>048 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7037001</name>
      <address>
        <city>Sabinov</city>
        <zip>08301</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7037003</name>
      <address>
        <city>Trnava</city>
        <zip>91701</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7037006</name>
      <address>
        <city>Vrutky</city>
        <zip>038 61</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Hungary</country>
    <country>Slovakia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 2, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <results_first_submitted>April 16, 2021</results_first_submitted>
  <results_first_submitted_qc>April 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 11, 2021</results_first_posted>
  <disposition_first_submitted>May 1, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>May 1, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 6, 2020</disposition_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT03332771/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 15, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT03332771/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 138 investigative sites in United States, Bulgaria, Hungary, and Slovakia from 01 December 2017 to 06 September 2019.</recruitment_details>
      <pre_assignment_details>Participants with diagnosis of Type 2 Diabetes Mellitus were enrolled in 1 of 4 treatment groups: Placebo or Sotagliflozin 200 mg or Sotagliflozin 400 mg or Glimepiride. Participants were randomly assigned in the ratio of 1:1:2:2 to these reporting groups. Total of 954 participants were enrolled in study, out of which 952 were randomized and treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Sotagliflozin 400 mg</title>
          <description>Following a 2-week run-in period, two Sotagliflozin 200 mg, tablets, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Sotagliflozin 200 mg</title>
          <description>Following a 2-week run-in period, one Sotagliflozin 200 mg, tablet and one Sotagliflozin-matching placebo tablet, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Glimepiride</title>
          <description>Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets, and combination of two Glimepiride capsules with adequate dose strengths per dose titration (titrated up to 6mg), taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="159"/>
                <participants group_id="P2" count="317"/>
                <participants group_id="P3" count="160"/>
                <participants group_id="P4" count="318"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="266"/>
                <participants group_id="P3" count="128"/>
                <participants group_id="P4" count="270"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="48"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor Compliance to Protocol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>At the Participant's own request</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The randomized population included any participant who had been allocated to a randomized treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Sotagliflozin 400 mg</title>
          <description>Following a 2-week run-in period, two Sotagliflozin 200 mg, tablets, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Sotagliflozin 200 mg</title>
          <description>Following a 2-week run-in period, one Sotagliflozin 200 mg, tablet and one Sotagliflozin-matching placebo tablet, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Glimepiride</title>
          <description>Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets, and combination of two Glimepiride capsules with adequate dose strengths per dose titration (titrated up to 6mg), taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="159"/>
            <count group_id="B2" value="317"/>
            <count group_id="B3" value="160"/>
            <count group_id="B4" value="318"/>
            <count group_id="B5" value="954"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.8" spread="11.2"/>
                    <measurement group_id="B2" value="59.7" spread="10.4"/>
                    <measurement group_id="B3" value="58.6" spread="9.9"/>
                    <measurement group_id="B4" value="59.8" spread="9.6"/>
                    <measurement group_id="B5" value="59.4" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="143"/>
                    <measurement group_id="B5" value="452"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="175"/>
                    <measurement group_id="B5" value="502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="111"/>
                    <measurement group_id="B5" value="297"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="230"/>
                    <measurement group_id="B3" value="106"/>
                    <measurement group_id="B4" value="207"/>
                    <measurement group_id="B5" value="653"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                    <measurement group_id="B2" value="269"/>
                    <measurement group_id="B3" value="136"/>
                    <measurement group_id="B4" value="277"/>
                    <measurement group_id="B5" value="823"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="224"/>
                    <measurement group_id="B3" value="121"/>
                    <measurement group_id="B4" value="230"/>
                    <measurement group_id="B5" value="693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c (HbA1c)</title>
          <units>percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.12" spread="0.73"/>
                    <measurement group_id="B2" value="8.09" spread="0.78"/>
                    <measurement group_id="B3" value="8.11" spread="0.86"/>
                    <measurement group_id="B4" value="8.07" spread="0.79"/>
                    <measurement group_id="B5" value="8.09" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure (SBP)</title>
          <units>millimeter of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133.23" spread="14.90"/>
                    <measurement group_id="B2" value="133.17" spread="14.37"/>
                    <measurement group_id="B3" value="132.78" spread="13.29"/>
                    <measurement group_id="B4" value="134.66" spread="14.43"/>
                    <measurement group_id="B5" value="133.61" spread="14.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hemoglobin A1c at Week 52</title>
        <description>An analysis of covariance (ANCOVA) model was used for the analysis.</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>Intend to treat (ITT) population included all randomized participants. Missing data are imputed using the retrieved dropouts imputation method.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sotagliflozin 400 mg</title>
            <description>Following a 2-week run-in period, two Sotagliflozin 200 mg, tablets, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Sotagliflozin 200 mg</title>
            <description>Following a 2-week run-in period, one Sotagliflozin 200 mg, tablet and one Sotagliflozin-matching placebo tablet, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Glimepiride</title>
            <description>Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets, and combination of two Glimepiride capsules with adequate dose strengths per dose titration (titrated up to 6mg), taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin A1c at Week 52</title>
          <description>An analysis of covariance (ANCOVA) model was used for the analysis.</description>
          <population>Intend to treat (ITT) population included all randomized participants. Missing data are imputed using the retrieved dropouts imputation method.</population>
          <units>percentage of HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="317"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="318"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.187"/>
                    <measurement group_id="O2" value="-0.65" spread="0.101"/>
                    <measurement group_id="O3" value="-0.49" spread="0.114"/>
                    <measurement group_id="O4" value="-0.61" spread="0.093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The change from baseline to Week 52 is analyzed using ANCOVA model with treatment groups, randomization strata of HbA1c (≤8.5, &gt;8.5%) at screening, randomization strata of SBP (&lt;130, ≥130 mmHg) at screening, and country as fixed effects, and baseline HbA1c as a covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority hypothesis was declared significant if the upper bound of the 2-sided 95% confidence interval (CI) for the adjusted mean difference is &lt;0.3.</non_inferiority_desc>
            <p_value>0.3306</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in Least Squares (LS) Mean</param_type>
            <param_value>0.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.122</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.120</ci_lower_limit>
            <ci_upper_limit>0.357</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The change from baseline to Week 52 is analyzed using ANCOVA model with treatment groups, randomization strata of HbA1c (≤8.5, &gt;8.5%) at screening, randomization strata of SBP (&lt;130, ≥130 mmHg) at screening, and country as fixed effects, and baseline HbA1c as a covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority hypothesis was declared significant if the upper bound of the 2-sided 95% CI for the adjusted mean difference is &lt;0.3.</non_inferiority_desc>
            <p_value>0.7112</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Mean</param_type>
            <param_value>-0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.114</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.265</ci_lower_limit>
            <ci_upper_limit>0.181</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hemoglobin A1c at Week 26</title>
        <description>An ANCOVA model was used for the analysis.</description>
        <time_frame>Baseline, Week 26</time_frame>
        <population>ITT population included all randomized participants. Missing data are imputed using the washout imputation method.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sotagliflozin 400 mg</title>
            <description>Following a 2-week run-in period, two Sotagliflozin 200 mg, tablets, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Sotagliflozin 200 mg</title>
            <description>Following a 2-week run-in period, one Sotagliflozin 200 mg, tablet and one Sotagliflozin-matching placebo tablet, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Glimepiride</title>
            <description>Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets, and combination of two Glimepiride capsules with adequate dose strengths per dose titration (titrated up to 6mg), taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin A1c at Week 26</title>
          <description>An ANCOVA model was used for the analysis.</description>
          <population>ITT population included all randomized participants. Missing data are imputed using the washout imputation method.</population>
          <units>percentage of HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="317"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="318"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.097"/>
                    <measurement group_id="O2" value="-0.77" spread="0.076"/>
                    <measurement group_id="O3" value="-0.61" spread="0.098"/>
                    <measurement group_id="O4" value="-1.02" spread="0.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The change from baseline to Week 26 is analyzed using ANCOVA model with treatment groups, randomization strata of HbA1c (≤8.5, &gt;8.5%) at screening, randomization strata of SBP (&lt;130, ≥130 mmHg) at screening, and country as fixed effects, and baseline HbA1c as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0827</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Mean</param_type>
            <param_value>-0.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.119</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.440</ci_lower_limit>
            <ci_upper_limit>0.027</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The change from baseline to Week 26 is analyzed using ANCOVA model with treatment groups, randomization strata of HbA1c (≤8.5, &gt;8.5%) at screening, randomization strata of SBP (&lt;130, ≥130 mmHg) at screening, and country as fixed effects, and baseline HbA1c as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Mean</param_type>
            <param_value>-0.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.103</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.571</ci_lower_limit>
            <ci_upper_limit>-0.167</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Week 26 and 52</title>
        <description>An ANCOVA model was used for the analysis.</description>
        <time_frame>Baseline, Week 26, Week 52</time_frame>
        <population>ITT population included all randomized participants. Missing data are imputed using the retrieved dropouts &amp; washout imputation method.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sotagliflozin 400 mg</title>
            <description>Following a 2-week run-in period, two Sotagliflozin 200 mg, tablets, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Sotagliflozin 200 mg</title>
            <description>Following a 2-week run-in period, one Sotagliflozin 200 mg, tablet and one Sotagliflozin-matching placebo tablet, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Glimepiride</title>
            <description>Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets, and combination of two Glimepiride capsules with adequate dose strengths per dose titration (titrated up to 6mg), taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Week 26 and 52</title>
          <description>An ANCOVA model was used for the analysis.</description>
          <population>ITT population included all randomized participants. Missing data are imputed using the retrieved dropouts &amp; washout imputation method.</population>
          <units>kilogram (kg)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="317"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="318"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.26" spread="0.329"/>
                    <measurement group_id="O2" value="-2.75" spread="0.257"/>
                    <measurement group_id="O3" value="-2.24" spread="0.336"/>
                    <measurement group_id="O4" value="0.70" spread="0.256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="1.406"/>
                    <measurement group_id="O2" value="-2.64" spread="0.503"/>
                    <measurement group_id="O3" value="-1.74" spread="0.707"/>
                    <measurement group_id="O4" value="0.94" spread="0.452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The change from baseline to Week 26 is analyzed using ANCOVA model with treatment groups (placebo, sotagliflozin 200 mg, sotagliflozin 400 mg, glimepiride), randomization strata of HbA1c (≤ 8.5, &gt;8.5%) at screening, randomization strata of SBP (&lt;130,≥ 130 mmHg) at screening, and country as fixed effects, and baseline body weight as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Mean</param_type>
            <param_value>-1.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.349</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.173</ci_lower_limit>
            <ci_upper_limit>-0.803</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The change from baseline to Week 52 is analyzed using analysis of ANCOVA model with treatment groups, randomization strata of HbA1c (≤8.5, &gt;8.5%) at screening, randomization strata of SBP (&lt;130, ≥130 mmHg) at screening, and country as fixed effects and baseline body weight as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Mean</param_type>
            <param_value>-3.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.544</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.651</ci_lower_limit>
            <ci_upper_limit>-2.517</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure (SBP) for Participants With SBP ≥130 mmHg at Week 12</title>
        <description>An ANCOVA model was used for the analysis.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Analysis was performed on ITT population in participants with baseline SBP ≥130 mmHg. Missing data are imputed using washout imputation method.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sotagliflozin 400 mg</title>
            <description>Following a 2-week run-in period, two Sotagliflozin 200 mg, tablets, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Sotagliflozin 200 mg</title>
            <description>Following a 2-week run-in period, one Sotagliflozin 200 mg, tablet and one Sotagliflozin-matching placebo tablet, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Glimepiride</title>
            <description>Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets, and combination of two Glimepiride capsules with adequate dose strengths per dose titration (titrated up to 6mg), taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure (SBP) for Participants With SBP ≥130 mmHg at Week 12</title>
          <description>An ANCOVA model was used for the analysis.</description>
          <population>Analysis was performed on ITT population in participants with baseline SBP ≥130 mmHg. Missing data are imputed using washout imputation method.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.34" spread="1.451"/>
                    <measurement group_id="O2" value="-8.03" spread="1.064"/>
                    <measurement group_id="O3" value="-9.12" spread="1.466"/>
                    <measurement group_id="O4" value="-3.86" spread="1.081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The change from baseline to Week 12 is analyzed using ANCOVA model with treatment groups, randomization strata of HbA1c (≤8.5, &gt;8.5%) at screening, and country as fixed effects, and baseline SBP as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Mean</param_type>
            <param_value>-4.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.288</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.701</ci_lower_limit>
            <ci_upper_limit>-1.650</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The change from baseline to Week 12 is analyzed using ANCOVA model with treatment groups, randomization strata of HbA1c (≤8.5, &gt;8.5%) at screening, and country as fixed effects, and baseline SBP as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0973</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Mean</param_type>
            <param_value>-2.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0973</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.890</ci_lower_limit>
            <ci_upper_limit>0.491</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure (SBP) for All Participants at Week 12</title>
        <description>An ANCOVA model was used for the analysis.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>ITT population included all randomized participants. Missing data are imputed using washout imputation method under the missing not at random framework.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sotagliflozin 400 mg</title>
            <description>Following a 2-week run-in period, two Sotagliflozin 200 mg, tablets, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Sotagliflozin 200 mg</title>
            <description>Following a 2-week run-in period, one Sotagliflozin 200 mg, tablet and one Sotagliflozin-matching placebo tablet, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Glimepiride</title>
            <description>Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets, and combination of two Glimepiride capsules with adequate dose strengths per dose titration (titrated up to 6mg), taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure (SBP) for All Participants at Week 12</title>
          <description>An ANCOVA model was used for the analysis.</description>
          <population>ITT population included all randomized participants. Missing data are imputed using washout imputation method under the missing not at random framework.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="317"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="318"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.64" spread="1.013"/>
                    <measurement group_id="O2" value="-4.70" spread="0.791"/>
                    <measurement group_id="O3" value="-4.77" spread="1.033"/>
                    <measurement group_id="O4" value="-0.68" spread="0.795"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The change from baseline to Week 12 is analyzed using ANCOVA model with treatment groups, randomization strata of HbA1c (≤ 8.5, &gt;8.5%) at screening, and country as fixed effects, and baseline SBP as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Mean</param_type>
            <param_value>-4.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.870</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.730</ci_lower_limit>
            <ci_upper_limit>-2.319</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With At Least One Documented Symptomatic Hypoglycemic Event</title>
        <description>Documented symptomatic hypoglycemia includes the typical symptoms of hypoglycemia (increased sweating, nervousness, asthenia/weakness, tremor, dizziness, increased appetite, palpitations, headache, sleep disorder, confusion, seizures, unconsciousness, and/or coma) and plasma glucose ≤ 70 mg/dL (3.9 mmol/L).</description>
        <time_frame>Up to Week 52</time_frame>
        <population>ITT population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sotagliflozin 400 mg</title>
            <description>Following a 2-week run-in period, two Sotagliflozin 200 mg, tablets, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Sotagliflozin 200 mg</title>
            <description>Following a 2-week run-in period, one Sotagliflozin 200 mg, tablet and one Sotagliflozin-matching placebo tablet, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Glimepiride</title>
            <description>Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets, and combination of two Glimepiride capsules with adequate dose strengths per dose titration (titrated up to 6mg), taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With At Least One Documented Symptomatic Hypoglycemic Event</title>
          <description>Documented symptomatic hypoglycemia includes the typical symptoms of hypoglycemia (increased sweating, nervousness, asthenia/weakness, tremor, dizziness, increased appetite, palpitations, headache, sleep disorder, confusion, seizures, unconsciousness, and/or coma) and plasma glucose ≤ 70 mg/dL (3.9 mmol/L).</description>
          <population>ITT population included all randomized participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="317"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="318"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63"/>
                    <measurement group_id="O2" value="1.26"/>
                    <measurement group_id="O3" value="3.75"/>
                    <measurement group_id="O4" value="16.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Weighted average of percentage difference between treatment groups from each stratum [randomization strata of HbA1c [≤8.5%, &gt;8.5%] at screening, randomization strata of mean SBP [&lt;130, ≥130 mmHg] at screening using Cochran-Mantel-Haenszel weights.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Percentage difference</param_type>
            <param_value>-15.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.67</ci_lower_limit>
            <ci_upper_limit>-11.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events (AEs)</title>
        <description>An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment.</description>
        <time_frame>Up to Week 52</time_frame>
        <population>Safety population included all participants who had received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sotagliflozin 400 mg</title>
            <description>Following a 2-week run-in period, two Sotagliflozin 200 mg, tablets, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Sotagliflozin 200 mg</title>
            <description>Following a 2-week run-in period, one Sotagliflozin 200 mg, tablet and one Sotagliflozin-matching placebo tablet, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Glimepiride</title>
            <description>Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets, and combination of two Glimepiride capsules with adequate dose strengths per dose titration (titrated up to 6mg), taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events (AEs)</title>
          <description>An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment.</description>
          <population>Safety population included all participants who had received at least one dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="317"/>
                <count group_id="O3" value="159"/>
                <count group_id="O4" value="317"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.2"/>
                    <measurement group_id="O2" value="59.9"/>
                    <measurement group_id="O3" value="56.6"/>
                    <measurement group_id="O4" value="49.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Hypoglycemic Events</title>
        <description>Percentage of participants with hypoglycemic events are reported for the following 3 categories: Any hypoglycemia (as reported in the Electronic Case Report Form); Documented symptomatic hypoglycemia [typical symptoms of hypoglycemia (increased sweating, nervousness, asthenia/weakness, tremor, dizziness, increased appetite, palpitations, headache, sleep disorder, confusion, seizures, unconsciousness, and/or coma) and plasma glucose ≤ 70 mg/dL (3.9 mmol/L)]; Severe [an event requiring assistance of another person to actively administer carbohydrate, glucagon, intravenous glucose or other resuscitative actions] or documented symptomatic hypoglycemia [typical symptoms of hypoglycemia and plasma glucose ≤ 70 mg/dL].</description>
        <time_frame>Up to Week 52</time_frame>
        <population>Safety population included all randomized participants who received at least 1 dose of double-blind investigational medicinal product (IMP) (regardless of the amount of treatment administered).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Sotagliflozin 400 mg</title>
            <description>Following a 2-week run-in period, two Sotagliflozin 200 mg, tablets, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Sotagliflozin 200 mg</title>
            <description>Following a 2-week run-in period, one Sotagliflozin 200 mg, tablet and one Sotagliflozin-matching placebo tablet, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Glimepiride</title>
            <description>Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets, and combination of two Glimepiride capsules with adequate dose strengths per dose titration (titrated up to 6mg), taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hypoglycemic Events</title>
          <description>Percentage of participants with hypoglycemic events are reported for the following 3 categories: Any hypoglycemia (as reported in the Electronic Case Report Form); Documented symptomatic hypoglycemia [typical symptoms of hypoglycemia (increased sweating, nervousness, asthenia/weakness, tremor, dizziness, increased appetite, palpitations, headache, sleep disorder, confusion, seizures, unconsciousness, and/or coma) and plasma glucose ≤ 70 mg/dL (3.9 mmol/L)]; Severe [an event requiring assistance of another person to actively administer carbohydrate, glucagon, intravenous glucose or other resuscitative actions] or documented symptomatic hypoglycemia [typical symptoms of hypoglycemia and plasma glucose ≤ 70 mg/dL].</description>
          <population>Safety population included all randomized participants who received at least 1 dose of double-blind investigational medicinal product (IMP) (regardless of the amount of treatment administered).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="317"/>
                <count group_id="O3" value="159"/>
                <count group_id="O4" value="317"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="4.1"/>
                    <measurement group_id="O3" value="6.3"/>
                    <measurement group_id="O4" value="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Documented symptomatic hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="1.3"/>
                    <measurement group_id="O3" value="3.8"/>
                    <measurement group_id="O4" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe or documented symptomatic hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                    <measurement group_id="O2" value="1.3"/>
                    <measurement group_id="O3" value="3.8"/>
                    <measurement group_id="O4" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First dose of study drug to last dose of study drug (up to 52 weeks) + 2 weeks</time_frame>
      <desc>Safety population included all participants who had received at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Sotagliflozin 400 mg</title>
          <description>Following a 2-week run-in period, two Sotagliflozin 200 mg, tablets, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Sotagliflozin 200 mg</title>
          <description>Following a 2-week run-in period, one Sotagliflozin 200 mg, tablet and one Sotagliflozin-matching placebo tablet, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Glimepiride</title>
          <description>Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets, and combination of two Glimepiride capsules with adequate dose strengths per dose titration (titrated up to 6mg), taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Incarcerated hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Vascular graft stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Vertebral osteophyte</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebellar stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adnexa uteri mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="317"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="317"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institution must provide any proposed publication or presentation to Sponsor for Sponsor's review, comment and approval at least thirty (30) days prior to the proposed submission for publication date or the proposed presentation date. Sponsor shall have the right to have deleted from the final version of the publication any confidential information, proprietary information, or patentable subject matter.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Affairs</name_or_title>
      <organization>Lexicon Pharmaceuticals, Inc.</organization>
      <phone>510-338-6064</phone>
      <email>medical-information@lexpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

